Synthesis and profile of SCH351591, a novel PDE4 inhibitor.
暂无分享,去创建一个
H. Dyke | J. Montana | J. Oxford | N. Cooper | F. Cuss | Motasim Billah | M. Minnicozzi | A. Ganguly | A. F. Haughan | N. Shih | J. Piwinski | L. Gowers | V. Sabin | R. Davenport | H. Kendall | C. Lowe | R. Naylor | K. Runcie | J. Warneck | Andrew Sharpe | D. Hannah | Robert Egan | J. Peake
[1] H. Dyke,et al. 8-Methoxyquinolines as PDE4 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.
[2] H. Dyke,et al. The therapeutic potential of PDE4 inhibitors. , 1999, Expert opinion on investigational drugs.
[3] J. Karlsson,et al. Phosphodiesterase 4 inhibitors for the treatment of asthma , 1997 .
[4] R. Egan,et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. , 1995, American journal of respiratory and critical care medicine.
[5] R. Egan,et al. Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. , 1993, The American review of respiratory disease.
[6] B. Costall,et al. Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs , 1987, Neuropharmacology.
[7] M. Brezinski,et al. Stereospecific binding of the antidepressant rolipram to brain protein structures. , 1986, European journal of pharmacology.